Use of ER selective NF-kB inhibitors for the treatment of sepsis
申请人:Caggiano J. Thomas
公开号:US20050256132A1
公开(公告)日:2005-11-17
The present invention provides methods for treating sepsis, systemic inflammatory response syndrome, severe sepsis, septic shock, and multiple organ dysfunction syndrome by modulating NF-κB transcription with ligands that interact with the estrogen receptor, preferably in the absence of classic estrogenic activity. Other aspects of the invention relate to methods for treating sepsis, systemic inflammatory response syndrome, severe sepsis, septic shock, and multiple organ dysfunction syndrome that comprise administering to a patient suffering therefrom an effective amount of a compound of Formula I:
Ionic liquid coated sulfonated carbon/silica composites: novel heterogeneous catalysts for organic syntheses in water
作者:Princy Gupta、Manmeet Kour、Satya Paul、James H. Clark
DOI:10.1039/c3ra45229h
日期:——
Ionicliquid coated sulfonic acid functionalized amorphous carbon/silica composites derived from a starch–glucose mixture were developed and their catalytic activities were evaluated for Knoevenagel condensation, reductive amination of aldehydes and ketones, and for Michael addition of indole to α,β-unsaturated ketones in aqueous medium. The catalyst prepared from starch–glucose mixture (3 : 1) [CSC-Star-Glu-IL2]
2-Cyanopropanoic acid amide and ester derivatives and methods of their use
申请人:Caggiano J. Thomas
公开号:US20050004164A1
公开(公告)日:2005-01-06
This invention provides compounds of formula I
or a pharmaceutically acceptable salt thereof that are useful for the treatment of the inflammatory component of diseases and are particularly useful in treating atherosclerosis, myocardial infarction, congestive heart failure, inflammatory bowel disease, arthritis, type II diabetes, and autoimmune diseases such as multiple sclerosis and rheumatiod arthritis.
2-Cyanopropanoic Acid Amide and Ester Derivatives and Methods of Their Use
申请人:Caggiano J. Thomas
公开号:US20070299105A1
公开(公告)日:2007-12-27
This invention provides compounds of formula I
or a pharmaceutically acceptable salt thereof that are useful for the treatment of the inflammatory component of diseases and are particularly useful in treating atherosclerosis, myocardial infarction, congestive heart failure, inflammatory bowel disease, arthritis, type II diabetes, and autoimmune diseases such as multiple sclerosis and rheumatoid arthritis.